• Explore /
  • Poster
  • / Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.

Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.

Abstract Poster

Authors

null

Nieves Martinez Lago

Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain

Nieves Martinez Lago , Borja Gonzalez , Elena Gallardo Martin , Ana Fernandez Montes , Antia Cousillas Castiñeira , Begona Grana Suarez , Alberto Carral Maseda , Maria Luz Pellon Augusto , Paula Gonzalez Villarroel , Juan De La Camara Gomez , Mercedes Salgado Fernández , Margarita Reboredo Lopez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 51)

DOI

10.1200/JCO.2024.42.3_suppl.51

Abstract #

51

Poster Bd #

D14

Abstract Disclosures

Similar Posters

First Author: Hirokazu Shoji

First Author: Yasutoshi Kuboki

First Author: Atsushi Ishiguro

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

First Author: Patrick M Boland